, Volume 58, Supplement 2, pp 395–396 | Cite as

Clinical Safety Profile of Grepafloxacin

  • H. Lode
  • F. Vogel
  • W. Elies
Poster Presentations Extended Abstract


  1. 1.
    Sader HS, Erwin ME, Jones RN. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. Eur J Clin Microbiol Infect Dis 1992; 11(4): 372–81PubMedCrossRefGoogle Scholar
  2. 2.
    Thornsberry C, Ogilvie P, Holley Jr HP. The activity of fluoroquinolones and other antimicrobial agents against community isolates of S. pneumoniae, H. influenzae and M. catarrhalis [abstract E-3]. Proceedings of the 37th Interscience Congress on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1: Toronto, CanadaGoogle Scholar
  3. 3.
    Ridgway GI, Salman H, Robbins MJ, et al. The in vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. J Antimicrob Chemother 1997; 40 Suppl. A: 31–4PubMedCrossRefGoogle Scholar
  4. 4.
    Efthymiopoulos C, Bramer SI, Maroli A. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy subjects. Clin Pharmacokinet 1997; 33 Suppl. 1: 1–8PubMedCrossRefGoogle Scholar
  5. 5.
    Chodosh S. Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infections. Clin Microbiol Infect 1998; 4 Suppl. 1: S25–S31PubMedCrossRefGoogle Scholar
  6. 6.
    Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Drug Saf 1995; 13(6): 343–58PubMedCrossRefGoogle Scholar
  7. 7.
    Shintani S, Kusunoki A, Hosoki E, et al. Drug interaction of OPC-17116, a new quinolone antibacterial agent, with nonsteroidal anti-inflammatory drugs in experimental animals [abstract 1479]. Proceedings of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; 1991 Sep 29–Oct 2: Chicago, IllinoisGoogle Scholar
  8. 8.
    Owen K. Comparative grepafloxacin phototoxicity in mouse skin. J Antimicrob Chemother 1998; 42(2): 261–4PubMedCrossRefGoogle Scholar
  9. 9.
    Owen K, Moult AB, Waldron MN. The comparative toxicity of fluoroquinolones in rats [abstract 47.021]. 8th International Congress for Infectious Diseases (ICID); 1998 May 15–18: Boston, USA: 127-8Google Scholar
  10. 10.
    Lode H, Vogel F, Elies W. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance. Clin Ther 1999; 21: 61–74PubMedCrossRefGoogle Scholar
  11. 11.
    Data on file, Glaxo WellcomeGoogle Scholar
  12. 12.
    Tschida SJ, Guay DR, Hoey LL, et al. QTc prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: aprospective evaluation and review of the literature. Pharmacotherapy 1996; 16(4): 663–74PubMedGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • H. Lode
    • 1
  • F. Vogel
    • 2
  • W. Elies
    • 3
  1. 1.Pneumologie I — Infektiologie und ImmunologieBerlinGermany
  2. 2.Medizinische Klinik III, Kliniken des Main-Taunus-KreisesKreiskrankenhaus Hofheim am TaunusGermany
  3. 3.Chefarzt Hals Nasen Ohren KlinikStaedtische Kliniken BielefeldGermany

Personalised recommendations